Burlington, Massachusetts, April 27, 2018 — MilliporeSigma today launched its new CellStream™ benchtop flow cytometry system, a compact, customizable flow cytometer that uses a camera for detection. Its unique optics system and design provide researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles.
“Researchers increasingly require more power and agility in their labs and research capabilities,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma. “MilliporeSigma’s new CellStream™ flow cytometry system expands the limits of sensitivity, allowing scientists to tailor their instrument to their needs in immunology, cancer research and many other areas.”
The CellStream™ system’s Amnis® time-delay integration and camera technology rapidly captures low-resolution cell images and converts them to high-throughput intensity data with enhanced fluorescence sensitivity. The new system can be used in a wide variety of research areas, including exosome research, where it can identify small populations unable to be seen on other cytometers.
MilliporeSigma developed this new technology with the same patent-protected optics system as its Amnis® flow cytometers, which are used in academic, biotech and pharmaceutical cell analysis and research applications.
The CellStream™ flow cytometry system offers multiple innovative features, including:
The new CellStream™ system expands MilliporeSigma’s portfolio of innovative flow cytometry platforms.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany generated sales of €15.3 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.